

OCT 14 1975



ALLENTOWN, PENNSYLVANIA 18105

13 October 1975

Dr. T. R. Torkelson
Dow Chemical Company
Health & Envir. Research
9000 Building
Midland, Michigan 48640

Dear Ted:

You will recall that when Dr. Tamburro made his presentation to the Research Coordinators at the HCA on 8 September 1975 under his Medical Surveillance Program he listed the following:

1. Biochemical
2. Radiology
3. Pulmonary
4. Cardiac
5. History and Physical

It is my opinion that most companies are not making a cardiac examination under their current medical surveillance of those people exposed to vinyl chloride. I think it pertinent that you or perhaps better Milton Freifeld ask each of the member companies in the HCA program whether cardiac examinations and specifically, EKG's are done.

Sincerely yours,

Mayo
W. Mayo Smith

MHS:cjm

cc: Milton Freifeld, HCA

ASI 00021968



Air Products and Chemicals
INC.

ALLENTOWN, PENNSYLVANIA 18105

OCT 20 1975

14 October 1975

Dr. T. A. Forkelson
Dow Chemical Company
Health & Envir. Research
9008 Building
Midland, Michigan 48667

Dear Ted:

Subject: Vinyl Chloride and Circulatory Aspects

This is further to my note to you and Milt Freifeld of 13 October. Attached is an article relating to KemaNord, the only PVC producer in Sweden and one of excellence.

You will recall that Nick Wheeler at our September meeting mentioned the ORC showed among fabricators according to my notes diseases of circulatory system to be higher than expected as 1,576 observed with expected 1,444. You may also remember that Laury Johnson thought these differences were significant.

The KemaNord report lends further evidence that we should immediately contact all member companies of the VCA Vinyl Chloride Program. My question of yesterday was whether any cardiac examinations are made and my question of today is what have been the findings, if so done.

With best regards,

Sincerely yours,

Mayo
H. Mayo Smith

MIS:cm

Attachment - Chemical Engineering, September 29, 1975

cc: Milton Freifeld, VCA

ASI 00021969